Novartis Corporation v. Webvention Holdings LLC et al

Filing 84

MEMORANDUM. Signed by Chief Judge Catherine C. Blake on 6/22/2015. Associated Cases: 1:11-md-02294-CCB, 1:11-cv-03620-CCB(jnls, Deputy Clerk)

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MARYLAND
NOVARTIS CORPORATION

v.

WEBVENTION HOLDINGS LLC &
WEBVENTION LLC

:
:
:
:
:
:
:
:

Civil No. CCB-11-3620

MEMORANDUM
Webvention Holdings LLC and Webvention LLC (collectively, “Webvention”) filed
separate lawsuits against several hundred defendants alleging infringement of its U.S. Patent No.
5,251,294 (“‘294 patent”).1 Before Webvention could bring a similar lawsuit against it—but
after Webvention had sent it a demand letter—Novartis Corporation filed a declaratory judgment
action against Webvention asking the court to declare that Novartis did not infringe the ‘294
patent and that the patent was invalid in the first instance. The United States Patent and
Trademark Office (“PTO”) recently reexamined the ‘294 patent for a third time and rejected the
patent claims asserted against Novartis. That rejection became final on September 24, 2014. In
light of that development, Novartis moved, on February 6, 2015, for judgment on the pleadings
and for a finding that this case was “exceptional” under 35 U.S.C. § 285.2 Before the court
decided Novartis’s motion, Webvention filed, on February 20, 2015, a covenant not to sue
Novartis for infringement of the ‘294 patent. (Statement of Non-Liability Regarding U.S. Patent
No. 5,251,294 (“Covenant”), ECF No. 75.) That same day, Webvention moved to dismiss for
lack of subject matter jurisdiction on the ground that its covenant mooted any actual controversy
in this case and that, accordingly, the court no longer had jurisdiction. Novartis argued the
1

A partial history of this case is outlined in the court’s June 15, 2012 memorandum. (See Mem. 1-4, ECF No. 52.)
Novartis also sought entry of a briefing schedule on attorneys’ fees and costs. The court approved Novartis’s
(corrected) proposed briefing schedule on February 9, 2015. (Order, ECF No. 73 (approving ECF No. 67).)
2

1

covenant did no such thing and, even if it did, it did not affect the court’s jurisdiction to hear
Novartis’s claim to attorneys’ fees. Noticing a procedural discrepancy, the court asked the
parties for clarification on the scope of Webvention’s motion. (Letter Order, ECF No. 81.) Both
parties provided responses. (Novartis Letter, ECF No. 82; Webvention Letter, ECF No. 83.)
Webvention’s motion is now ripe, and a hearing is not needed to resolve it. See Local Rule
105.6 (D. Md. 2014). For the reasons stated below, Webvention’s infringement counterclaim
will be dismissed with prejudice under Rule 41(a)(2), Webvention’s motion will be granted, and
Novartis’s motion for judgment on the pleadings will be denied as moot. But the court finds that
Novartis is the “prevailing party” within the meaning of section 285. Accordingly, the court will
continue to hear Novartis’s request for attorneys’ fees.
ANALYSIS
I. Motion to Dismiss
The Declaratory Judgment Act provides that “[i]n a case of actual controversy within its
jurisdiction, . . . any court of the United States . . . may declare the rights and other legal relations
of any interested party seeking such declaration, whether or not further relief is or could be
sought.” 28 U.S.C. § 2201(a). “A party seeking to base jurisdiction on the Declaratory
Judgment Act bears the burden of proving that the facts alleged, ‘under all the circumstances,
show that there is a substantial controversy, between . . . parties having adverse legal interests, of
sufficient immediacy and reality to warrant the issuance of a declaratory judgment.’” Benitec
Australia, Ltd. v. Nucleonics, Inc., 495 F.3d 1340, 1343 (Fed. Cir. 2007) (quoting MedImmune,
Inc. v. Genentech, Inc., 549 U.S. 118, 127 (2007)). The declaratory judgment plaintiff bears the
burden of establishing that such jurisdiction “existed at the time the claim for declaratory relief
was filed and that it has continued since.” Id. at 1344 (citations omitted).

2

The parties did not dispute that Novartis met its burden when it first filed this action.
Even though it had yet to sue Novartis for infringement, Webvention had already sent Novartis a
demand letter seeking $80,000 for a one-time license on the ‘294 patent. (See Novartis’s Mot.
Ex. A, ECF No. 71-1.) In response, Novartis filed its declaratory judgment action “to avoid the
threat of a ‘scarecrow’ patent,” which was enough to establish jurisdiction. Cardinal Chem. Co.
v. Morton Int’l, Inc., 508 U.S. 83, 96 (1993). Further, after Webvention filed its infringement
counterclaim on May 2, 2011, “there [wa]s, necessarily, a case or controversy adequate to
support jurisdiction . . . under the [Declaratory Judgment] Act.” Id. (emphasis in original).
But the parties differed—at least before the court asked the parties for clarification on
Webvention’s motion, as explained further below—as to whether the court had jurisdiction after
Webvention filed its covenant not to sue. “As the Supreme Court has recognized, a covenant not
to sue a declaratory judgment plaintiff can moot a controversy between the parties.” Organic
Seed Growers & Trade Ass’n v. Monsanto Co., 718 F.3d 1350, 1357 (Fed. Cir. 2013); see also
Dow Jones & Co. v. Ablaise Ltd., 606 F.3d 1338, 1346 (Fed. Cir. 2010) (“[A] covenant not to
sue for patent infringement divests the trial court of subject matter jurisdiction over claims that
the patent is invalid, because the covenant eliminates any case or controversy between the
parties.”). Whether such jurisdiction is divested, however, “depends on what is covered by the
covenant.” Revolution Eyewear, Inc. v. Aspex Eyewear, Inc., 556 F.3d 1294, 1297 (Fed. Cir.
2009). Jurisdiction is divested if the covenant is broad enough in scope such that the court “is
satisfied that it is ‘absolutely clear’ that the allegedly unlawful activity cannot reasonably be
expected to recur.” Already, LLC v. Nike, Inc., 133 S. Ct. 721, 729 (2013). Jurisdiction is not
divested, however, if the covenant includes gaps or caveats that “preserve[] th[e] controversy at a
level of ‘sufficient immediacy and reality[.]’” Revolution Eyewear, 556 F.3d at 1300 (holding

3

that jurisdiction had not been ousted when patentee “offered no covenant on the current products,
[and] stat[ed] that it [wa]s not obligated to ‘repudiate suit for future infringement.’”).
Webvention argued its covenant not to sue covered enough to moot Novartis’s
declaratory judgment action. That covenant states:
Webvention . . . unconditionally agrees . . . not to sue Novartis . . . , or any of its
successors-in-interest or officers or directors, or any customers, licensees and
sublicensees of Novartis, for infringement of [the ‘294 patent] based upon any
past, present, or future research, development, testing, manufacture, use, sale or
offer for sale of any product which Novartis has advertised, commercially
manufactured, marketed or sold, including without limitation the products and/or
uses in issue in this litigation.
(Covenant, at 1.) On its face, “[t]he breadth of this covenant suffice[d]” to moot the action.
Already, 133 S. Ct. at 728. Like the covenant examined by the Supreme Court in Already,
Webvention’s covenant is “unconditional and irrevocable.” Id. It covers past, present, and
future activity. It covers all manner of Novartis’s uses. And “it reaches beyond [Novartis] to
protect [Novartis]’s [licensees] and customers.” Id.
But Webvention had not yet mooted Novartis’s case. Webvention’s declaration had
bound it “not to sue” Novartis on the ‘294 patent in the future, but included no language about its
pending infringement counterclaim. Cf. Samsung Elecs. Co. v. Rambus, Inc., 440 F. Supp. 2d
495, 504 (E.D. Va. 2006) (“The covenants not to sue extinguished the case or controversy with
respect to a declaratory judgment of non-infringement and unenforceability, but not with respect
to Rambus’ infringement claim.”). And Webvention had not moved to dismiss that counterclaim
under Federal Rule of Civil Procedure 41(a)(2).
Because Webvention had not asked for dismissal of that infringement counterclaim—yet
in the same breath was arguing the court no longer had subject matter jurisdiction—the court
ordered the parties to “show cause why Webvention’s motion [to dismiss] should not also be

4

construed as requesting voluntary dismissal of its infringement counterclaim under [Rule]
41(a)(2).” (Letter Order, at 1.) Webvention “confirm[ed]” that its motion “include[d] a request
that Webvention’s counterclaims be dismissed under [Rule] 41(a)(2).” (Webvention Letter, at
1.) Novartis “d[id] not object” to that construction. (Novartis Letter, at 1.) Accordingly, the
court will now dismiss, with prejudice, Webvention’s infringement counterclaim under Rule
41(a)(2).
Once the court has dismissed Webvention’s counterclaim, Webvention will have
completely mooted Novartis’s declaratory judgment action. See, e.g., Dodge-Regupol, Inc. v. RB
Rubber Prods., Inc., 585 F. Supp. 2d 645, 649-51 (M.D. Pa. 2008). Accordingly, the court will
grant Webvention’s motion to dismiss for lack of subject matter jurisdiction, and deny as moot
Novartis’s motion for judgment on the pleadings.
II. Attorneys’ Fees Under Section 285
The parties disagree on the consequences of granting Webvention’s motion to dismiss.
Specifically, they disagree as to whether Novartis can still seek attorneys’ fees under section 285.
That section provides that “[t]he court in exceptional cases may award reasonable attorney fees
to the prevailing party.” 35 U.S.C. § 285.
To the extent Webvention argues that the court’s decision to grant its motion to dismiss
for lack of subject matter jurisdiction also ousts jurisdiction over Novartis’s section 285-related
motions, Webvention is incorrect. The court retains independent jurisdiction over such motions.
See Monsanto Co. v. Bayer Bioscience N.V., 514 F.3d 1229, 1242 (Fed. Cir. 2008) (“Even if
filing such a covenant may divest the court of jurisdiction over a declaratory judgment action
regarding these patents, under our precedent the district court retained independent jurisdiction
over Monsanto’s request for attorney fees under 35 U.S.C. § 285.” (citations omitted)); Highway

5

Equip. Co. v. FECO, Ltd., 469 F.3d 1027, 1033 n.1 (Fed. Cir. 2006) (“While the covenant may
have eliminated the case or controversy pled in the patent-related counterclaim . . . , the covenant
does not deprive the district court of jurisdiction to determine the disposition of . . . the request
for attorney fees under 35 U.S.C. § 285.” (citations omitted)).
Nevertheless, Novartis must show that it is the “prevailing party” to proceed under
section 285. See Inland Steel Co. v. LTV Steel Co., 364 F.3d 1318, 1319-20 (Fed. Cir. 2004).
Novartis believes it is “clearly” the prevailing party for two reasons. First, Novartis “effectively
has obtained the result on liability that it sought” when the PTO rejected the asserted ‘294 claims
in a “final, unappealable decision[.]” (Novartis Letter, at 2.) Second, dismissal with prejudice of
Webvention’s counterclaim under Rule 41(a)(2) “legally altered the relationship between the
parties” in a way sufficient to make Novartis the prevailing party. (Id.) Webvention disagrees,
arguing that Novartis “did not prevail on any issue,” and the ‘294 claims were held invalid due to
the PTO’s actions, not as a result of anything Novartis did.3 (Webvention Letter, at 1.)
Federal Circuit law “define[s] the meaning of prevailing party in the context of patent
litigation.” Inland Steel, 364 F.3d at 1320 (quoting Manildra Milling Corp. v. Ogilvie Mills,
Inc., 76 F.3d 1178, 1181 (Fed. Cir. 1996)). To be the “prevailing party,” the Federal Circuit
requires: “(1) that the party ‘received at least some relief on the merits,’ and (2) ‘[t]hat relief
must materially alter the legal relationship between the parties by modifying one party’s
behavior in a way that “directly benefits” the opposing party.’” SSL Servs., LLC v. Citrix Sys.,

3

Earlier, Webvention argued that “a ‘prevailing party’ can only be determined after the case is completed.”
(Webvention Mot. Dismiss 3, ECF No. 76.) To the extent Webvention believes that the court cannot even reach the
question of who is the prevailing party because “no judgment has been entered in favor of Novartis in this
proceeding, . . . nor can one be entered[,]” (id. at 4), Webvention is incorrect. “The dismissal of a claim with
prejudice . . . is a judgment on the merits under the law of the Federal Circuit.” Highway Equip. Co., 469 F.3d at
1035 (quoting Power Mosfet Techs., L.L.C. v. Siemens AG, 378 F.3d 1396, 1416 (Fed. Cir. 2004)).

6

Inc., 769 F.3d 1073, 1086 (Fed. Cir. 2014) (quoting Shum v. Intel Corp., 629 F.3d 1360, 1367
(Fed. Cir. 2010)).
The court concludes that Novartis is clearly the prevailing party here. At the outset, the
Federal Circuit has explicitly held that, “as a matter of patent law, the dismissal with prejudice,
based on [a] covenant and granted pursuant to [a] district court’s discretion under Rule 41(a)(2),
has the necessary judicial imprimatur to constitute a judicially sanctioned change in the legal
relationship of the parties” sufficient to bestow “prevailing party status” on an accused infringer.
Highway Equip. Co., 469 F.3d at 1035. Even without that explicit holding, the facts of this case
confirm that Novartis is the prevailing party. Novartis has received substantial relief on the
merits that has materially altered its relationship to Webvention. Simply put, the court’s order
dismissing, with prejudice, Webvention’s infringement counterclaim will preclude Webvention
from ever suing or threatening to sue Novartis for infringement of the ‘294 patent; Webvention’s
behavior has been modified, and Novartis directly benefits from that modification. See Samsung
Elecs. Co., 440 F. Supp. 2d at 511 (“A Rule 41(a)(2) dismissal is a court order that materially
alters the legal relationship between the parties . . . [and] bears the necessary judicial imprimatur.
The necessary conclusion then is that the voluntary dismissal with prejudice in this case made
Samsung the prevailing party under 35 U.S.C. § 285.”); Classen Immunotherapies, Inc. v. Biogen
Idec, Civ. No. WDQ-04-2607, 2014 WL 2069653, at *4 (D. Md. May 14, 2014)4 (“Following
the Court’s dismissal with prejudice of Classen's claims against it, Biogen will be the ‘prevailing
party’ under § 285, because it has obtained—in its favor—a judicially sanctioned material
alteration of its relationship with Classen.” (citations omitted)).
Because the court concludes that Novartis is the “prevailing party” within the meaning of
section 285, the court may hear any claim by Novartis for attorneys’ fees. The court notes,
4

Unpublished cases are cited only for the soundness of their reasoning, not for any precedential value.

7

however, that such a claim “must be processed in compliance with Rule 54(d)(2)(B).” IPXL
Holdings, L.L.C. v. Amazon.com, Inc., 430 F.3d 1377, 1386 (Fed. Cir. 2005). Simply put, “[n]o
provision in section 285 exempts requests for attorney fees thereunder from compliance with
Rule 54(d)(2)(B).” Wedgetail Ltd. v. Huddleston Deluxe, Inc., 576 F.3d 1302, 1306 (Fed. Cir.
2009) (quoting id.). And Rule 54(d)(2)(B) states that any motion for attorneys’ fees must: “be
filed no later than 14 days after entry of judgment”; “specify the judgment and the statute, rule,
or other grounds entitling the moving party to the award”; and “state the amount or provide a fair
estimate of the amount sought.” Fed. R. Civ. P. 54(d)(2)(B).
Although it is clear that Novartis seeks an attorneys’ fee award, its pending motion for an
exceptional case finding, standing alone, does not appear to comply with Rule 54(d)(2)(B). As
an initial matter, because it was filed before the court’s present dismissal order, Novartis’s
motion was premature. Even assuming it had been filed after the present order, the motion
neither specifies the judgment entitling Novartis to an award nor states even an estimate of the
amount it seeks. While the court recognizes that Novartis filed—and the court approved—
Novartis’s proposed briefing schedule for attorneys’ fees, that action alone does not cure the
procedural deficiency. See Wedgetail Ltd., 576 F.3d at 1306 (“Despite [Rule 54(d)(2)(B)’s]
requirements, Huddleston did not file a motion for attorney fees . . . , but instead merely
requested that the district court set a briefing schedule for such a motion.”). Accordingly, the
court will deny that motion without prejudice. Such dismissal does not, however, preclude
Novartis from now refiling a procedurally compliant motion for fees.
CONCLUSION
For the reasons stated above, the court will dismiss with prejudice Webvention’s
infringement counterclaim under Rule 41(a)(2). Because such dismissal completely moots

8

Novartis’s declaratory judgment action, Webvention’s motion to dismiss will be granted, and
Novartis’s motion for judgment on the pleadings will be denied as moot.
Because the court finds that Novartis is the “prevailing party” within the meaning of
section 285, the court may continue to hear Novartis’s request for attorneys’ fees. Because,
however, Novartis’s pending motion for an exceptional case finding does not comply with Rule
54(d)(2)(B), that motion will be denied without prejudice. If Novartis still seek attorneys’ fees, it
may do so by refiling a motion that complies with Rule 54 within the next 14 days, or longer if it
obtains a court-ordered extension.5
A separate Order follows.

June 22, 2015
Date

5

/S/
Catherine C. Blake
United States District Judge

That motion should include Novartis’s arguments on exceptionality.

9